Silverback Therapeutics Inc
NASDAQ:SBTX
Intrinsic Value
Silverback Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. [ Read More ]
The intrinsic value of one SBTX stock under the Base Case scenario is 7.73 USD. Compared to the current market price of 5.87 USD, Silverback Therapeutics Inc is Undervalued by 24%.
Valuation Backtest
Silverback Therapeutics Inc
Run backtest to discover the historical profit from buying and selling SBTX stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Silverback Therapeutics Inc
| Current Assets | 277.7m |
| Cash & Short-Term Investments | 274.4m |
| Other Current Assets | 3.3m |
| Non-Current Assets | 3.7m |
| PP&E | 774k |
| Other Non-Current Assets | 3m |
| Current Liabilities | 5.4m |
| Accounts Payable | 3.4m |
| Accrued Liabilities | 1.7m |
| Other Current Liabilities | 283k |
| Non-Current Liabilities | 3.1m |
| Other Non-Current Liabilities | 3.1m |
Earnings Waterfall
Silverback Therapeutics Inc
|
Revenue
|
1.3m
USD
|
|
Operating Expenses
|
-36.8m
USD
|
|
Operating Income
|
-35.5m
USD
|
|
Other Expenses
|
834k
USD
|
|
Net Income
|
-34.7m
USD
|
Free Cash Flow Analysis
Silverback Therapeutics Inc
What is Free Cash Flow?
SBTX Profitability Score
Profitability Due Diligence
Silverback Therapeutics Inc's profitability score is 24/100. The higher the profitability score, the more profitable the company is.
Score
Silverback Therapeutics Inc's profitability score is 24/100. The higher the profitability score, the more profitable the company is.
SBTX Solvency Score
Solvency Due Diligence
Silverback Therapeutics Inc's solvency score is 69/100. The higher the solvency score, the more solvent the company is.
Score
Silverback Therapeutics Inc's solvency score is 69/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
SBTX Price Targets Summary
Silverback Therapeutics Inc
Ownership
SBTX Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
SBTX Price
Silverback Therapeutics Inc
| Average Annual Return | 88.29% |
| Standard Deviation of Annual Returns |
N/A
|
| Max Drawdown | -95% |
| Market Capitalization | 208.2m USD |
| Shares Outstanding | 35 473 800 |
| Percentage of Shares Shorted | 3.95% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Silverback Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in Seattle, Washington and currently employs 90 full-time employees. The company went IPO on 2020-12-04. The firm is focused on leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The Company’s lead virology product candidate, SBT8230, is an ASGR1-TLR8 ImmunoTAC therapeutic. SBT8230 is comprised of an ASGR1 monoclonal antibody conjugated to a Toll-like receptor 8 (TLR8) linker-payload. SBT8230 is designed to elicit an anti-viral immune response by targeting TLR8 activation to the liver. SBT8230 antibody designed to recognize an epitope distinct from that bound by the ASGR1 ligand, GalNAc, allowing for possible combination of SBT8230. The Company’s platform enables the strategic pairing of proprietary payloads that modulate key disease modifying pathways with monoclonal antibodies directed at specific disease sites.
Contact
IPO
Employees
Officers
The intrinsic value of one SBTX stock under the Base Case scenario is 7.73 USD.
Compared to the current market price of 5.87 USD, Silverback Therapeutics Inc is Undervalued by 24%.
You don't have any saved screeners yet
